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Survival andMorbidity of Preterm Children Born at 22
Through 34Weeks’ Gestation in France in 2011
Results of the EPIPAGE-2 Cohort Study
Pierre-Yves Ancel, PhD; François Goffinet, PhD; and the EPIPAGE-2Writing Group
IMPORTANCE Up-to-date estimates of the health outcomes of preterm children are needed
for assessing perinatal care, informing parents, making decisions about care, and providing
evidence for clinical guidelines.
OBJECTIVES To determine survival and neonatal morbidity of infants born from 22 through
34 completed weeks’ gestation in France in 2011 and compare these outcomes with a
comparable cohort in 1997.
DESIGN, SETTING, AND PARTICIPANTS The EPIPAGE-2 study is a national, prospective,
population-based cohort study conducted in all maternity and neonatal units in France in
2011. A total of 2205 births (stillbirths and live births) and terminations of pregnancy at 22
through 26weeks’ gestation, 3257 at 27 through 31 weeks, and 1234 at 32 through 34 weeks
were studied. Cohort data were collected from January 1 through December 31, 1997, and
fromMarch 28 through December 31, 2011. Analyses for 1997 were run for the entire year and
then separately for April to December; the rates for survival andmorbidities did not differ.
Data are therefore presented for the whole year in 1997 and the 8-month and 6-month
periods in 2011.
MAIN OUTCOMES ANDMEASURES Survival to discharge and survival without any of the
following adverse outcomes: grade III or IV intraventricular hemorrhage, cystic periventricular
leukomalacia, severe bronchopulmonary dysplasia, retinopathy of prematurity (stage 3 or
higher), or necrotizing enterocolitis (stages 2-3).
RESULTS A total of 0.7% of infants born before 24 weeks’ gestation survived to discharge:
31.2% of those born at 24 weeks, 59.1% at 25 weeks, and 75.3% at 26 weeks. Survival rates
were 93.6% at 27 through 31 weeks and 98.9% at 32 through 34 weeks. Infants discharged
homewithout severe neonatal morbidity represented 0% at 23 weeks, 11.6% at 24 weeks,
30.0% at 25 weeks, 47.5% at 26 weeks, 81.3% at 27 through 31 weeks, and 96.8% at 32
through 34 weeks. Compared with 1997, the proportion of infants surviving without severe
morbidity in 2011 increased by 14.4% (P < .001) at 25 through 29weeks and 6% (P < .001) at
30 through 31 weeks but did not change appreciably for those born at less than 25 weeks.
The rates of antenatal corticosteroid use, induced preterm deliveries, cesarean deliveries, and
surfactant use increased significantly in all gestational-age groups, except at 22 through 23
weeks.
CONCLUSIONS AND RELEVANCE The substantial improvement in survival in France for
newborns born at 25 through 31 weeks’ gestation was accompanied by an important
reduction in severe morbidity, but survival remained rare before 25 weeks. Although
improvement in survival at extremely low gestational agemay be possible, its effect on
long-term outcomes requires further studies. The long-term results of the EPIPAGE-2 study
will be informative in this regard.
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P revious cohort studies1-7 suggest that survival of in-fantsbornbefore27weeks’ gestationhas improveddur-ing the past 2 decades. However, disability rates re-
main high at these gestational ages.8-10 Moreover, countries
differ substantially in their organization of care, available re-
sources,national laws, andcultural preferences regardingpro-
vision of proactive care. Therefore, to provide the best avail-
able information forparents andmedical staff touse inmaking
treatment decisions, mortality and morbidity must be moni-
tored, and studies should be conducted in countrieswith dif-
ferent attitudes toward active care at early gestational ages.
By far,most of the important cohort studies11-13 in the field
have focused exclusively on infants born before 27 weeks’
gestation. However, even though infants born between 27
and 31 weeks are at lower relative risk of adverse outcomes,
they represent a much larger proportion of preterm births.
Hence, in absolute numbers, they account for most children
with deficits.
We present the results of the EPIPAGE-2 (Etude Epidémi-
ologique sur les Petits Ages Gestationnels 2) study, a national
cohort of infants born at a gestational age of 22 through 34
weeks in France in 2011. Our objectives were to study sur-
vival andsurvivalwithoutsevereneonatalmorbidities.Wealso
looked at perinatal interventions and compared the out-
comeswith thoseof a similar cohort from1997, theEPIPAGE-1
study.13 Our hypothesis was that survival and survival with-
out severe morbidity have improved during the past 15 years
in France, except for extremely preterm infants.
Methods
Ethics
Recruitment and data collection occurred only after families
hadreceived informationandagreedtoparticipate in thestudy.
This studywas approved by the National Data Protection Au-
thority (Commission Nationale de l’Informatique et des Lib-
ertés) and by the appropriate ethics committees (Consulta-
tive Committee on the Treatment of Information on Personal
HealthData forResearchPurposes andCommittee for thePro-
tection of People Participating in Biomedical Research). Par-
ticipants provided oral informed consent.
Study Design and Population Study
EPIPAGE-2 is a national, prospective, population-based study
scheduled to followuppretermchildren to the ageof 12 years.
Infants born at 22 through 34 completed weeks’ gestation in
Francewere eligible for inclusion. Only one region,which ac-
counts for 2% of all births in France, did not participate. The
study began March 28, 2011. Recruitment took place at birth
in all maternity units in the participating regions. The num-
ber of infants required according to our sample size
calculations14 was provided by an 8-month recruitment pe-
riod for births at 22 through 26weeks, a 6-monthperiod for 27
through31weeks, anda5-weekperiod for32 through34weeks.
During recruitment, members of the regional coordinating
committees visited all maternity units to ensure the identifi-
cation of all eligible children.
The births in our study population were defined to com-
prise live births, stillbirths, and terminations of pregnancy for
maternal (severematernal diseases) or fetal (severe growth re-
striction and oligohydramnios) reasons other than congeni-
tal anomalies. In all, 2381 birthswere eligible at 22 through 26
weeks, 3478 at 27 through 31weeks, and 1376 at 32 through 34
weeks, with 176, 221, and 142 parental refusals, respectively.
The study thus included 2205 births at 22 through 26 weeks,
3257 at 37 through 31weeks, and 1234 at 32 through 34weeks.
Total births in the 25 French regions in 2011 (National Insti-
tute of Statistics and Economic Studies; http://www.insee.fr
/fr/) were used to estimate preterm birth rates, taking into ac-
count months of inclusion and differences in recruitment
periods according to gestational age at birth.
Data Collection
In each center, one obstetric and one pediatric study coordi-
nator were responsible for data acquisition, validation, and
quality control. Datawere collected frommedical records and
obstetric and neonatal staff. Data on stillbirths and termina-
tions of pregnancywere collected at the timeof delivery.Data
on live-born infantswere collected prospectively during hos-
pitalization until discharge or death. Gestational age was de-
fined as the best obstetric estimate combining lastmenstrual
periodandultrasonogramassessment.Extensivedatawerecol-
lected about pregnancy, delivery, and the neonatal period to
investigate pregnancy complications, decisions about termi-
nations of pregnancy, the child’s condition at birth, neonatal
diseases, organization of care, treatment, and attitudes to-
wardcare.Onlyselectedperinataldatawereconsidered for this
study: level of care of the institution, antenatal corticosteroid
use, vaginal or cesarean delivery, indicated preterm delivery
(defined as a birth after induction of labor or cesarean deliv-
ery before theonset of labor), anduseof surfactants andpost-
natal corticosteroids. Questionnaireswere completed online,
with a secure interface that protected the confidentiality and
privacy of data and personal information. The EPIPAGE coor-
dination team used a centralized system tomonitor and vali-
date inclusion and data collection at the national level.
OutcomeMeasures
Theprimaryoutcomewas infant survival, definedas thenum-
ber of children discharged home alive. The secondary out-
comewas survival to dischargewithout severe neonatalmor-
bidity. Severe neonatal morbidity was defined as any of the
followingoutcomes: severe intraventricularhemorrhage (IVH),
definedas IVHassociatedwithventricular dilatation (grade III
IVH)and intraparenchymalhemorrhage (ie, largeunilateralpa-
renchymal hyperdensity or a large unilateral porencephalic
cyst)15; cystic periventricular leukomalacia (cPVL) (ie, peri-
ventricular white matter echolucencies at ultrasonography);
stages II and III necrotizingenterocolitis, according to the stag-
ing of Bell et al16; stage 3 or higher retinopathy of prematu-
rity, according to the international classification17 and/or la-
ser treatment; and/or severe bronchopulmonary dysplasia
(BPD), defined as administrationof oxygen for at least 28days
plus need for 30% or more oxygen and/or mechanical venti-
latory support or continuous positive airway pressure at 36
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weeks’ postmenstrual age.18 Among infants admitted to the
neonatal intensive care unit (NICU), 98.0% of survivors born
before 33 weeks, 88.0% of those born at 33 weeks, and 66.0%
of those born at 34 weeks had at least one cranial ultrasono-
gram assessment. Survivors at 33 and 34 weeks without cra-
nial ultrasonogram assessment were considered not to have
severe cerebral lesions, and thosewithno funduscopic exami-
nationwere considerednot tohave severe retinopathyof pre-
maturity.
Comparison of French Birth Cohorts Between 1997 and 2011
In 1997, theEPIPAGE-1 study, a comparableprospective, popu-
lation-basedcohort study, tookplace in9 regionsofFrance.13,19
Eligible infants for this comparison are those born alive be-
tween 22 and 34 weeks’ gestation from the 1997 and 2011 co-
horts in the same 9 regions. Outcome measures are survival
todischarge and survivalwithoutneonatalmorbidity. The lat-
terwas defined as above, except for BPD (oxygen supplemen-
tation at 36 weeks’ postmenstrual age) because information
on its severitywasnot available in 1997. Cohort datawere col-
lected from January 1 through December 31, 1997, and from
March 28 throughDecember 31, 2011.14Analyses for 1997were
run for the entire year and then separately forApril toDecem-
ber; the rates for survival andmorbidities did not differ. Data
are therefore presented for the whole year in 1997 and the
8-month and 6-month periods in 2011.
Statistical Analysis
Datareportedonthebirthcertificate (ie,gestationalageatbirth,
vital status at birth, andneonatal death)wereavailable andus-
ablewithout parental consent for childrennot included in the
study.Wecompared the survival of theparticipating andnon-
participating (because of parent refusal) newborns. Then, for
the infants whose parents agreed to participate, we analyzed
survival todischarge, severeneonatalmorbidity, survivalwith-
out severe morbidity, and some obstetric and neonatal inter-
ventions, according togestational age.Toexamine trendsover
time, we compared survival and neonatal morbidity in the
EPIPAGE-1 study19with those in the EPIPAGE-2 study accord-
ing to gestational age. For each week of gestation, we report
exact 95% binomial CIs of survival rates and their differ-
ences. All tests were 2-sided; P < .05 was considered statisti-
cally significant. All statistical analyses were performedwith
SAS statistical software, version 9.3 (SAS Institute Inc).
Results
Preterm Birth Rates
In 2011, preterm birth rates were 4.4 per 1000 total stillbirths
and livebirths and2.1per 1000 livebirthsbefore 27weeks’ ges-
tation, 8.4 and 7.5 at 27 through 31 weeks, and 17.8 and 17.3 at
32 through 34 weeks, respectively.
Comparison of Study Participants and Nonparticipants
Participationrateswere92.6%amonginfantsbornat22 through
26 weeks, 93.6% among those at 27 through 31 weeks, and
89.7% among those at 32 through 34 weeks. In each gesta-
tionalagegroup, theproportionof livebirthswasslightlyhigher
amongparticipants thannonparticipants. Survival among live
birthsdidnotdiffer significantlybetween the2groups (eTable
1 in the Supplement).
Status at Birth and Perinatal Deaths
The proportion of live-born infants increased with gesta-
tionalage from13.5%at22weeks to98.5%at34weeks (Table 1).
Only one infant born at 22 through 23 weeks (ie, 0.1% of all
births and 0.7% of live births) survived to discharge (Table 1).
Survival rates were 14.4% of all births and 31.2% of live births
at 24weeks, 41.8% and 59.1% at 25weeks, 59.6% and 75.3% at
26weeks, 73.7%and86.3%at 27 through28weeks, 88.0%and
96.6% at 29 through 31 weeks, and 96.7% and 98.9% at 32
through 34weeks, respectively (Table 1). Among infants who
died, theproportionwhosedeaths followedadecision to limit
intensive care varied from 80.9% at 22 through 24weeks and
70.3%at 25 through 26weeks to 57.0%at 27 through 31weeks.
Themedian age at death was the day of birth for infants born
at 22 through 24weeks, 5 days (interquartile range, 1-16 days)
for those born at 25 through 26 weeks, and 7 days (interquar-
tile range, 1-22 days) for those born at 27 through 31 weeks.
Perinatal Interventions
Among the live-born infants at 22 weeks, 36.2% were born in
level III hospitals compared with 61.8% at 23 weeks, 77.4% at
24weeks, 85.0% at 25 through 26weeks, 84.8% at 27 through
31 weeks, and 50.1% at 32 through 34weeks (Table 2). Among
extremelypreterminfantsnotborn ina level IIIhospital, 54.3%
were postnatally transferred to a NICU; this proportion var-
ied from4.3%at 22 through23weeks to45.3%at 24weeks and
90.7% at 25 through 26 weeks. Postnatal transfers to a NICU
reached 91.8%at 27 through 29weeks but decreased to 56.3%
at 30 through 31weeks and 17.0%at 32 through 34weeks. The
percentageof infants exposed toantenatal corticosteroidswas
very low at 22 (1.8%) and 23 (12.3%) weeks but increased to
56.7%at 24weeks and 78.4%at 25 through 26weeks (Table 2).
Cesarean rateswere 6.3% at 22 through 23weeks and 13.5% at
24 weeks compared with 34.0% at 25 weeks and 59.9% at 26
weeks; this rate reached69.8%at 27 through 31weeks. Fewof
the infantsbornat22 through23weekswereadmitted toNICUs
(6.1%); this percentage increased to 60.8%at 24weeks, 91.9%
at 25 weeks, 95.6% at 26 weeks, and 98.9% at 27 through 31
weeks. Among infants admitted to the NICU, 96.7% of those
bornat 24 through26weeks received surfactant and24.0%re-
ceived postnatal corticosteroids.
Neonatal Morbidity
Of survivors at 24 through 26 weeks, 12.9% had severe IVH,
2.4% had cPVL, 25.6% had severe BPD, 6.0% had retinopathy
of prematurity stage 3 or higher, and 5.1%had stage 2 or 3 nec-
rotizingenterocolitis (Table3). In thisgroup, 299 infants (59.2%
of survivors and 34.1% of live births) were discharged home
withoutsevereneonatalmorbidity.Thepercentageof suchsur-
vivors ranged from 0% at 23 weeks to 65.3% (47.5% of live
births) at 26weeks (Figure 1). Of the 206 infantswho survived
with severe neonatal conditions, 23.8% had 2 or more condi-
tions. Of survivors at 27 through 31weeks, 2254 (87.6%; 81.3%
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of live births)were discharged homewithout severe neonatal
morbidity; the percentage of survivors ranged from 71.9%
(57.6%of livebirths) at 27weeks to93.5% (90.6%of livebirths)
at 31weeks (Figure 1). Among the 320 infantswith severeneo-
natal morbidities, 8.4% had 2 or more morbidities. At 32
through34weeks, 1080 infants (97.9%of survivors and96.8%
of live births)were discharged homewithout severe neonatal
morbidity. One infant had 2 severe conditions.
Trends Between 1997 and 2011
Among infants born alive at 22 through 23 weeks in the 9 re-
gions studied in 1997, none survived in 1997 or 2011, and the
chance of survival at 24 weeks did not change between the
studies (Figure 2A and eTable 2 in the Supplement). Survival
increased in these regions by 11.2% (95% CI, −0.5% to 22.9%)
at 25 weeks, 18.1% (95% CI, 8.2% to 28.1%) at 26 weeks, 12.8%
(95% CI, 4.8% to 20.8%) at 27 weeks, 12.3% (95% CI, 6.1% to
18.6%) at 28 weeks, 7.1% (95% CI, 2.7% to 11.5%) at 29 weeks,
4.7% (95% CI, 1.4% to 8.0%) at 30 weeks, and 2.1% (95% CI,
−0.2% to4.4%) at 31weeks. Althoughmedian age at deathdid
not change at 22 through 24 weeks, it increased significantly
at 25 through 26weeks. Between 1997 through 2011, the rates
of antenatal corticosteroid use, indicated preterm deliveries,
and surfactant use increased significantly in all gestational-
age groups, except at 22 through 23 weeks (Figure 2C-E and
eTable 3 in the Supplement).
Survival without neonatal morbidity did not change sig-
nificantly at 24 weeks between 1997 (2.4%) and 2011 (7.4%)
(Figure 2B). It increased by 16.2% (95% CI, 6.7% to 25.8%) at
25 weeks, 19.0% (95% CI, 9.1% to 28.8%) at 26 weeks, 16.3%
(95% CI, 6.4% to 26.2%) at 27 weeks, 17.8% (95% CI, 9.2% to
26.5%) at 28weeks, 16.6% (95%CI, 8.7% to 24.5%) at 29weeks,
6.3% (95% CI, 0.7% to 11.8%) at 30 weeks, and 5.9% (95% CI,
1.8% to 10.1%) at 31 weeks. Among survivors at 24 through 26
weeks, the rates of necrotizing enterocolitis (P = .005), BPD
(P = .004), cPVL, and severe retinopathy of prematurity de-
creased between 1997 and 2011, althoughnot significantly for
the cPVL (P = .07) and severe retinopathy of prematurity (P =
.11) (eTable 4 in the Supplement). At 27 through 31weeks, the
prevalence of cPVLdecreasedby 3% (P < .001) andBPDby4%
(P < .001). Only cPVL decreased among infants born at 32
through 34 weeks (P = .03) (eTable 4 in the Supplement).
Discussion
The results of the EPIPAGE-2 study, a national, prospective,
population-basedcohort studyofbirthsat22 through34weeks’
gestation, indicate that survival and survival without severe
neonatalmorbidity improved significantly between 1997 and
2011 for infants born at 25 through 31 weeks. By contrast, nei-
ther survival nor survivalwithoutmorbidity improved for in-
fants born before 25 weeks.
The strengths of the EPIPAGE-2 study include the popu-
lation-based cohort design and prospective enrollment of in-
fants born prematurely in France in 2011. Standardized defi-
nitionsofoutcomesandsystematic andprospective collection
ofall informationavailable (eg,all cranialultrasonograms) from
a national sample of more than 8000 preterm births (22-34
weeks’ gestation) allowed us to look at the effects associated
with a wide range of gestational ages on survival and on ma-
jorneonatalmorbidities inourpopulation.Theaccuracyof the
gestational age estimates was improved by the very high rate
(>98%) of women with early ultrasonogram assessments.
Table 1. Vital Status at Birth, Deaths, and Survival by Gestational Age in 2011
Gestational
Age, wk
No. (%) of Events
All Infants
(N = 6696) TOPa (n = 214)
Stillbirthsa
(n = 1313)
Live Birthsa
(n = 5169)
Deaths in
Maternity Wardb
(n = 289)
Deaths in
NICUb
(n = 413)
Survival to Dischargeb,c
(n = 4467)
22 430 53 (12.3) 319 (74.2) 58 (13.5) 56 (96.6) 2 (3.4) 0
23 414 43 (10.4) 282 (68.1) 89 (21.5) 82 (92.1) 6 (6.7) 1 (1.1) [0-3.3]
24 404 40 (9.9) 178 (44.1) 186 (46.0) 73 (39.2) 55 (29.6) 58 (31.2) [24.5-37.8]
25 435 28 (6.4) 99 (22.8) 308 (70.8) 25 (8.1) 101 (32.8) 182 (59.1) [53.6-64.6]
26 522 24 (4.6) 85 (16.3) 413 (79.1) 18 (4.4) 84 (20.3) 311 (75.3) [71.1-79.5]
22-26 2205 188 (8.5) 963 (43.7) 1054 (47.8) 254 (24.1) 248 (23.5) 552 (52.4) [49.4-55.4]
27 478 11 (2.3) 67 (14.0) 400 (83.7) 9 (2.3) 62 (15.5) 329 (82.3) [78.5-86.0]
28 526 6 (1.1) 63 (12.0) 457 (86.9) 6 (1.3) 40 (8.8) 411 (89.9) [87.2-92.7]
29 561 4 (0.7) 48 (8.6) 509 (90.7) 6 (1.2) 17 (3.3) 486 (95.5) [93.7-97.3]
30 761 5 (0.7) 75 (9.9) 681 (89.5) 2 (0.3) 19 (2.8) 660 (96.9) [95.6-98.2]
31 931 0 69 (7.4) 862 (92.6) 8 (0.9) 18 (2.1) 836 (97.0) [95.8-98.1]
27-31 3257 26 (0.8) 322 (9.9) 2909 (89.3) 31 (1.1) 156 (5.4) 2722 (93.6) [92.7-94.5]
32 281 0 10 (3.6) 271 (96.4) 1 (0.4) 4 (1.5) 266 (98.2) [96.6-99.8]
33 363 0 9 (2.5) 354 (97.5) 1 (0.3) 2 (0.6) 351 (99.2) [98.2-100]
34 590 0 9 (1.5) 581 (98.5) 2 (0.3) 3 (0.5) 576 (99.1) [98.4-99.9]
32-34 1234 0 28 (2.3) 1206 (97.7) 4 (0.3) 9 (0.7) 1193 (98.9) [98.3-99.5]
Abbreviations: NICU, neonatal intensive care unit; TOP, termination of
pregnancy for maternal and fetal reasons (other than congenital anomalies).
a Related to all births.
b Related to live births.
c Numbers in brackets are 95% binomial CIs for the percentage of patients.
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One limitation is that 7% of eligible infants were not in-
cludedbecause of parental refusal.However, the survival sta-
tus of all patients, including thosewho refused to participate,
wasavailable.Furthermore, thepercentageof survival in these
2 groups did not differ significantly. Therefore, the effect of
this selection was very slight.
These 2 EPIPAGE studies13,19 made it possible to deter-
mine the changes in mortality and morbidity between 1997
through 2011. We studied neonatal conditions known to be
prognostic for long-termoutcomes. Although the studies had
a commondesign,more extensive datawere collected in 2011
than in 1997.Hence,wemayhaveunderestimatedchangesbe-
tween the 2 periods for survival without morbidity and mor-
bidity rates in general. However, because we restricted our
comparisons to severe neonatal conditions, defined similarly
in each study, we assume that the influence of this difference
was slight.
One important result of our study is that less than 1% of
infants born at 22 through 23 weeks survived. In this popula-
tion, 80.9% of deaths occurred after a decision to limit inten-
sive care,mostlywithin the first dayof life. The general policy
in France is not to intervene before 24 weeks’ gestation;
infants born earlier receive palliative but not intensive
care.20 We compared French results with those of large con-
temporary international studies1,2,4,6,7,21 conducted in the
middle to late 2000s (eTable 5 in the Supplement). The more
active perinatal management at the limit of viability in other
countries has resulted in higher survival rates than those in
our population at extremely preterm gestational ages.1,2,4,6,7
At 24 weeks, survival remained low in France, reflecting the
lack of consensus and heterogeneity of perinatal manage-
ment for these infants. In this group, as among those born at
22 through 23 weeks, deaths occurred within a day of birth
after a decision to limit intensive care. This timing contrasts
with the timing of death in those countries that report high
rates of perinatal interventions and survival.1,2,6,7 Active
perinatal interventions and survival became more frequent
in France at 25 weeks, but survival rates remained higher in
the United States, Japan, and Sweden up to a gestational age
of 27 weeks.5,6
Table 2. Perinatal Characteristics and Obstetric and Neonatal Interventions by Gestational Age in 2011a
Gestational
Age, wk
Multiple
Birthb
Birth Weight,
Median
(IQR), gc
Birth in
Level III
Maternityb
Antenatal
Corticosteroid
Useb
Indicated
Preterm
Deliveryb,d
Cesarean
Deliveryb
Surfactant
Usee
Postnatal
Corticosteroid
Usef
Length of
Hospital
Stay,
Median
(IQR), wke
22 20/58
(34.5)
490
(438-523)
21/58
(36.2)
1/57
(1.8)
8/57
(14.0)
5/57
(8.8)
1/2
(50.0)
0/2
(0)
0
23 31/89
(34.8)
570
(510-620)
55/89
(61.8)
10/81
(12.3)
8/88
(9.1)
4/87
(4.6)
5/7
(71.4)
0/7
(0)
147
24 52/186
(28.0)
680
(618-730)
144/186
(77.4)
101/178
(56.7)
20/182
(11.0)
24/178
(13.5)
108/112
(96.4)
30/109
(27.5)
119
(109-141)
25 121/308
(39.3)
760
(700-830)
258/308
(83.8)
225/298
(75.5)
71/303
(23.4)
103/303
(34.0)
270/278
(97.1)
75/273
(27.5)
104
(90-123)
26 114/413
(27.6)
860
(750-940)
355/413
(86.0)
328/407
(80.6)
153/400
(38.3)
246/411
(59.9)
375/389
(96.4)
78/379
(20.6)
92
(82-105)
22-26 338/1054
(32.1)
750
(633-860)
833/1054
(79.0)
665/1021
(65.1)
260/1030
(25.2)
382/1036
(36.9)
759/788
(96.3)
183/770
(23.8)
98
(87-119)
27 135/400
(33.8)
970
(806-1070)
347/400
(86.8)
315/389
(81.0)
183/382
(47.9)
277/396
(69.9)
347/388
(89.4)
53/373
(14.2)
81
(70-98)
28 142/457
(31.1)
1090
(950-1220)
400/457
(87.5)
386/452
(85.4)
224/446
(50.2)
320/456
(70.2)
364/448
(81.3)
32/432
(7.4)
70
(62-84)
29 149/509
(29.3)
1240
(1050-1370)
449/509
(88.2)
424/503
(84.3)
274/492
(55.7)
356/508
(70.1)
327/501
(65.3)
23/487
(4.7)
59
(51-70)
30 208/681
(30.5)
1370
(1160-1530)
593/681
(87.1)
561/668
(84.0)
376/655
(57.4)
488/678
(72.0)
312/673
(46.4)
12/658
(1.8)
50
(43-60)
31 294/862
(34.1)
1540
(1310-1710)
678/862
(78.7)
713/841
(84.8)
465/827
(56.2)
578/854
(67.7)
324/841
(38.5)
8/830
(1.0)
41
(36-50)
27-31 928/2909
(31.9)
1260
(1040-1500)
2467/2909
(84.8)
2399/2853
(84.1)
1522/2802
(54.3)
2019/2892
(69.8)
1674/2851
(58.7)
128/2780
(4.6)
55
(44-70)
32 125/271
(46.1)
1710
(1520-1939)
162/271
(59.8)
220/264
(83.3)
130/257
(50.6)
177/269
(65.8)
54/264
(20.5)
2/261
(0.8)
34
(28-40)
33 124/354
(35.0)
1920
(1710-2120)
175/354
(49.4)
271/345
(78.6)
163/336
(48.5)
202/354
(57.1)
57/346
(16.5)
0/341
(0)
26
(21-32)
34 197/581
(33.9)
2150
(1920-2370)
267/581
(46.0)
376/569
(66.1)
265/564
(47.0)
280/578
(48.4)
38/561
(6.8)
0/563
(0)
16
(12-22)
32-34 446/1206
(37.0)
1985
(1720-2230)
604/1206
(50.1)
867/1178
(73.6)
558/1157
(48.2)
659/1201
(54.9)
149/1171
(12.7)
2/1165
(0.2)
23
(16-32)
Abbreviation: IQR, interquartile range.
a Data are presented as number of events/number in group (percentage) unless
otherwise indicated. Denominators vary according to the number of missing
data for each variable.
b Related to live births.
c Birth weight is missing for 6 infants born at 23 through 26weeks' gestation
and 2 infants born at 27 through 31 weeks' gestation.
d Indicated preterm delivery: birth after induction of labor or cesarean delivery
before the onset of labor.
e Estimated in days among survivors: only for length of hospital stay.
f Related to infants admitted to neonatal intensive care units: only for
surfactant use and postnatal corticosteroid use.
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International comparisons emphasize that the potential
for survival among extremely preterm infants is 10% to 50%
higher than our results. They also suggest that active man-
agement of extremely preterm infants can improve survival
for those born at higher gestational ages. In France, the
extension of withholding care to less premature infants,
because of fears about immediate and long-term adverse
outcomes, might also explain our results at 25 through 27
weeks. However, results of comparisons such as those noted
above should be interpreted with caution because differ-
ences in gestational age measurement and in the distinction
between stillbirths and live births cannot be excluded.22
One way to clarify the role of these issues would be to
design multinational cohort studies with standardized
methods. In addition, meta-analysis of outcomes using
patient-level data might allow better assessment of country-
level differences in outcomes.
There is a widespread consensus that the aim of neona-
tal care should be to resuscitate infants with a reasonable
likelihood of an acceptable quality of life, but identification
of strategies for better outcomes remains difficult. Uncer-
tainty about long-term outcomes at the limit of viability
influences treatment decisions at extremely low gestational
ages in France. The results of previous studies6,23-25 of
trends in short-term morbidity and longer-term outcomes
of infants born at gestational ages close to this limit make it
difficult to predict the effect of a more proactive manage-
ment of these infants on their survival without morbidity.
Hence, consideration of this potential effect must examine
the possible and problematic nature of the trade-off
between improved survival and increased risk of severe
long-term adverse health outcomes for infants born before
25 weeks.
Figure 1. SurvivalWithout Severe Neonatal Morbidity in 2011
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For each week of gestation, percentages and exact 95% binomial CIs (error
bars) are presented.
Table 3. Severe Neonatal Morbidity According to Gestational Age Among Survivors to Discharge in 2011a
Gestational
Age, wk
No. of Events/No. in Group (%)
Grade III
IVH or IPH Cystic PVL Severe BPD Severe ROP Severe NEC
No. of Severe Neonatal Morbidities
0 1 ≥2
23 0/1
(0)
0/1
(0)
1/1
(100.0)
0/1
(0)
1/1
(100.0)
0/1
(0)
0/1
(0)
1/1
(100.0)
24 13/58
(22.4)
1/58
(1.7)
19/51
(37.3)
10/58
(17.2)
3/57
(5.3)
21/51
(41.2)
17/51
(33.3)
13/51
(25.5)
25 26/180
(14.4)
4/182
(2.2)
47/168
(28.0)
17/180
(9.4)
10/181
(5.5)
90/165
(54.5)
57/165
(34.5)
18/165
(10.9)
26 32/310
(10.3)
8/311
(2.6)
64/292
(21.9)
6/308
(1.9)
14/310
(4.5)
188/288
(65.3)
83/288
(28.8)
17/288
(5.9)
23-26 71/549
(12.9)
13/552
(2.4)
131/512
(25.6)
33/547
(6.0)
28/549
(5.1)
299/505
(59.2)
157/505
(31.1)
49/505
(9.7)
27 26/326
(8.0)
9/327
(2.8)
49/311
(15.8)
4/325
(1.2)
17/323
(5.3)
220/306
(71.9)
74/306
(24.2)
12/306
(3.9)
28 16/404
(4.0)
10/406
(2.5)
30/391
(7.7)
1/408
(0.2)
19/402
(4.7)
315/380
(82.9)
58/380
(15.3)
7/380
(1.8)
29 24/477
(5.0)
10/482
(2.1)
16/466
(3.4)
1/482
(0.2)
17/483
(3.5)
399/459
(86.9)
57/459
(12.4)
3/459
(0.7)
30 17/651
(2.6)
10/654
(1.5)
13/644
(2.0)
0/655
(0)
21/651
(3.2)
572/629
(90.9)
56/629
(8.9)
1/629
(0.2)
31 16/819
(2.0)
9/823
(1.1)
12/821
(1.5)
1/830
(0.1)
19/831
(2.3)
748/800
(93.5)
48/800
(6.0)
4/800
(0.5)
27-31 99/2677
(3.7)
48/2692
(1.8)
120/2633
(4.6)
7/2700
(0.3)
93/2690
(3.5)
2254/2574
(87.6)
293/2574
(11.4)
27/2574
(1.0)
32 2/251
(0.8)
3/253
(1.2)
0/261
(0)
0/261
(0)
2/260
(0.8)
236/242
(97.5)
6/242
(2.5)
0/242
(0)
33 1/350
(0.3)
4/350
(1.1)
0/342
(0)
0/345
(0)
6/339
(1.8)
317/328
(96.6)
11/328
(3.4)
0/328
(0)
34 4/574
(0.7)
2/574
(0.3)
0/560
(0)
0/564
(0)
2/544
(0.4)
527/533
(98.9)
5/533
(0.9)
1/533
(0.2)
32-34 7/1175
(0.6)
9/1177
(0.8)
0/1163
(0)
0/1170
(0)
10/1143
(0.9)
1080/1103
(97.9)
22/1103
(2.0)
1/1103
(0.1)
Abbreviations: BPD, bronchopulmonary dysplasia; IPH, intraparenchymal
hemorrhage; IVH, intraventricular hemorrhage; NEC, necrotizing enterocolitis;
PVL, periventricular leukomalacia; ROP, retinopathy of prematurity.
a Denominators vary according to the number of missing data for each variable.
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Results of our trend study during a 15-year period (1997-
2011) reveal that survivalwithoutmorbidity increasedby14.1%
for infants born at 25 through 29 weeks. This finding indi-
cates that 1 of every 7 infants had a more favorable outcome
in 2011 compared with 1997. Hence, the total number of chil-
dren surviving without short-term and perhaps also long-
term severe adverse outcomes has increased over time.
Conclusions
Few other population-based studies from around the world
provide up-to-date estimates of short-term prognosis of ex-
tremely, very, andmoderately preterm infants andof changes
during thepast decade. International comparisonshelp to es-
timate thepotential for survival and to identify appropriate in-
terventions; they thus reveal areas for improvement in each
country. In particular, they reveal that improvement in sur-
vival at extremely lowgestational age is possible inFranceand
in countries with similar practices. This finding should en-
couragehealth careprofessionals to reassess their attitudes to-
ward care at extremely low gestational ages. This reassess-
ment should includeacompleteanalysisofneonatalmorbidity
and long-term sequelae,which have not yet been sufficiently
evaluated, although they remain important factors in deci-
sion making. EPIPAGE-2 should provide further information
on them as the children it studies age. Finally, specificities in
the organization of care, health policies, laws, and available
resources of each country must also be part of this discus-
sion.
Figure 2. Comparison of Survival Rates andObstetric and Neonatal Interventions in 1997 and 2011
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For each week of gestation, percentages and exact 95% binomial CIs (error
bars) are presented. A, Survival to discharge; B, survival to discharge without
morbidity; C, antenatal corticosteroid use; D, cesarean deliveries; E, surfactant
use; and F, postnatal corticosteroid use.
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